Liver Cancer 100: Fundamentals of Liver Cancer Care
Image For Activity Cover
Availability
On-Demand
3 Courses
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credits
0.5 Attendance Credit
1.5 Participation Credits
  • Description
  • Accreditation Information
  • Faculty and Disclosures
The Liver Cancer 100 Series is a compilation of short video interviews covering several topics regarding hepatocellular carcinoma (HCC). They include a variety of therapeutic options, including embolization, radioembolization, immunotherapy, radiation, and ablation, and the pathology of HCC. This series of activities will serve as valuable resources specifically targeted to hepatologists and others participating on the HCC care team. This information will also help practitioners explain aspects of care to patients.
Each activity will be accredited for CME and will be accredited for .25 or .5 AMA PRA Category 1 CreditTM.

This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Allie Cao, MD
Nothing to Disclose

Amy Kim, MD
Scientific Consultant: AstraZeneca

Andrew Moon, MD, MPH
Scientific Consultant: Target RWE, IDEOlogy, Eisai
Data Safety Monitoring Board: Intercept
Grant/Research Support: DCN Diagnostics

Anjana Pillai, MD, FAASLD
Scientific Consultant: Replimune, Genentech, Exelixis, Inc., Eisai, Inc., AstraZeneca, Gilead, Boston Scientific
Medical Advisory Board: AstraZeneca, Genentech
Speakers Bureau: Gilead

Charles Kim, MD
Baylis Medical, ACI Humacyte, Kriya Therapeutics

Daniella Sia, PhD
Nothing to Disclose

David Kaplan, MD, FAASLD, FACP, AGAF
Scientific Consultant: Roche Genentech, Sirtex, AstraZeneca, Exelixis
Grant/Research Support: Exact Sciences, AstraZeneca, Glycotest, Inc., Bausch, Gilead

Jeffery Meyer, MD
Intellectual Property Rights: UpToDate, Springer

Julius Chapiro MD, PhD
Scientific Consultant: Guerbet, Bayer, AstraZeneca, Eisai

Kara Wegermann, MD
Scientific Consultant: Focus Medical

Neeraja Kannan, APRN
Nothing to Disclose

Nicole Kim, MD, MPH
Grant/Research Support: Madrigal Pharmaceutical

Nima Kokabi, MD
Scientific Consultant: Boston Scientific, Galvanize Therapeutics, Okami Medical, Sirtex Medical, Terumo Medical
Grant/Research Support: Sirtex Medical
Speaker's Bureau: Sirtex Medical, Okami Medical

Omobonike Oloruntoba-Sanders, MD
Nothing to Disclose

Rachna Shroff, MD
Taiho, QED, Elevar Therapeutics

Sumera Ilyas, MD
Scientific Consultant: AstraZeneca, AstraZeneca Janssen

Veronica Nguyen, MD
Nothing to Disclose

Yuko Kono, MD, PhD, FAASLD
Grant/Research Support: Canon Medical, Bracco Diagnostics

Zachary Goodman, MD, PhD, FAASLD
Nothing to Disclose



STAFF:

Steven Folstein, MFA, M Ed.
Nothing to Disclose

Wendy Risso, MPH
Nothing to Disclose

Sally Cook, CMP, CHCP
Nothing to Disclose

Powered By